Yung Shin Pharm. Ind

CompanyTaiwan

Yung Shin Pharm. Ind develops one asset, approved (tenofovir disoproxil fumarate in chronic hepatitis B). Mostly small molecule acting on OCA2 and pol; based in Taiwan.

1
Asset
Furthest stage
Approved
4
Trials
9
Signals

Pipeline

1
  • tenofovir disoproxil fumarate

    Prodrug of tenofovir that inhibits hepatitis B viral polymerase, blocking viral DNA synthesis.

    Approved, Small molecule, OCA2, pol, chronic hepatitis B, hepatitis b virus

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials4
  • Signals20
  • Similar companies6

Intelligence